Indium-(111in) Oxinate Curium

Indium-111 oxine, the active ingredient in Indium-(111in) Oxinate Curium, is a radiopharmaceutical presented as an injectable solution for intravenous use. It labels white blood cells, providing a radioactive marker that enables scintigraphic imaging of infection and inflammation in patients.

GNH USA supplies Indium-(111in) Oxinate Curium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory documentation for import. Products are shipped with temperature monitoring to ensure integrity during transit.

Indium-111 oxine is used in diagnostic imaging to label leukocytes for detecting infection and inflammatory conditions. - Infection: Enables detection of bacterial or fungal infection sites via labeled leukocyte scintigraphy. - Inflammation: Allows visualization of inflammatory processes such as osteomyelitis, prosthetic joint infection, and soft‑tissue abscesses. - Febrile neutropenia: Assists in locating the source of fever in neutropenic patients when conventional imaging is inconclusive.

Indium-111 oxine may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain: Mild discomfort at the infusion site. - Transient fever: Low‑grade temperature rise within 24 hours. - Nausea: Mild, self‑limiting nausea. - Headache: Brief headache not requiring treatment.

Serious or Rare Side Effects: - Allergic reaction: Rash, pruritus, or urticaria indicating hypersensitivity. - Anaphylaxis: Rare but potentially life‑threatening systemic reaction. - Radiation‑induced marrow suppression: Decrease in blood cell counts, especially with repeated studies. - Severe infection: Exacerbation of underlying infection due to manipulation of leukocytes.

When using Indium-111 oxine, several safety considerations should be observed to protect patients and staff. - Pregnancy: Use only if the potential diagnostic benefit outweighs fetal radiation risk. - Breastfeeding: Discontinue nursing or pump and discard milk for 24 hours after administration. - Renal impairment: Monitor renal function as excretion may be delayed, increasing radiation exposure. - Radiation safety: Follow institutional radiation protection protocols, including shielding and waste disposal. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 oxine can interact with other agents that affect radiation exposure or leukocyte function.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: Co‑administration can lead to cumulative radiation dose exceeding safety limits. - Myelosuppressive chemotherapy: Combined effect may increase risk of hematologic toxicity.

Moderate Interactions (Monitor Closely): - Antibiotics influencing leukocyte activity: May alter labeling efficiency and image quality. - Immunosuppressants: Reduced leukocyte counts can diminish tracer uptake. - Contrast agents used in imaging: May interfere with scintigraphic interpretation.